Alzheimer's patients often have an alteration in plasma proteins involved in a blood clotting and inflammation pathway. We will determine how prevalent these alterations are in AD patients, when they arrear during the course of the disease, and if their presence is correlated with specific aspects of the disease.  Treatment of these altered proteins in the subset of AD patients that exhibit these alterations could be beneficial.